A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-11

Study Completion Date

2025-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body.

This study is seeking participants who have any of the following cancer types:

* non-small cell lung cancer
* colorectal cancer
* bladder cancer
* melanoma (a type of skin cancer)
* kidney cancer
* head and neck cancer Participants will receive the study medicine PF-07921585 alone or in combination with another study medicine called sasanlimab at the study clinic.

PF-07921585 will be given as an infusion into a vein or as shots under the skin, once every 3 weeks. Sasanlimab will be given as shots under the skin, also once every 3 weeks.

The experiences of participants receiving the study medicine will be studied to help see if the study medicine is safe and effective. Participants may receive study medicine for up to 2 years, depending on how the cancer responds to the study treatment. Participants may continue receiving study medicine after 2 years if there are any benefits from the study treatment. Participants will attend visits once every 3 weeks with the first 9 weeks having more frequent visits, to check the safety of the study treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591

Breast Neoplasms Prostate Neoplasms Neoplasms, Squamous Cell +6 more

TERMINATED PHASE1

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

NCT07121829

Melanoma Solid Tumor Pilocytic Astrocytoma +7 more

TERMINATED PHASE1

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

NCT00118170

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Burkitt Lymphoma +42 more

COMPLETED PHASE1

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00119249

Stage III Melanoma Stage IV Melanoma

COMPLETED PHASE2

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

NCT00245102

Adult Angiosarcoma Adult Epithelioid Sarcoma Adult Leiomyosarcoma +12 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study contains 3 parts:

Part 1: dose escalation of PF-07921585 as single agent to determine the monotherapy recommended dose for further study.

Part 2: dose escalation of PF-07921585 in combination with the anti-PD 1 inhibitor sasanlimab and potentially other anti-cancer agents, in order to determine the recommended dose for expansion of the combination.

Part 3: dose optimization/ expansion will evaluate PF-07921585 in combination with sasanlimab, and potentially other anti-cancer agents. After identification of the recommended dose for expansion in Part 2, participants with select solid tumors will be enrolled into 3-4 cohorts as follows:

* Cohort 1: Melanoma
* Cohort 2: Microsatellite stable (MSS) metastatic colorectal cancer
* Cohort 3: Non-small cell lung cancer (NSCLC)
* Cohort 4: Solid tumor, tumor types and clinical setting to be determined based on emerging data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer Bladder Cancer Renal Cell Carcinoma Melanoma Head and Neck Cancer Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1

Dose escalation monotherapy

Group Type EXPERIMENTAL

PF-07921585

Intervention Type BIOLOGICAL

IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously

Part 2

Dose escalation (combination therapy)

Group Type EXPERIMENTAL

PF-07921585

Intervention Type BIOLOGICAL

IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously

Sasanlimab

Intervention Type BIOLOGICAL

Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously

Part 3

Dose optimization/ expansion (combination therapy)

Group Type EXPERIMENTAL

PF-07921585

Intervention Type BIOLOGICAL

IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously

Sasanlimab

Intervention Type BIOLOGICAL

Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-07921585

IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously

Intervention Type BIOLOGICAL

Sasanlimab

Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PF-06801591

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants aged ≥18 years or older at the time of informed consent.
2. Tumor types and prior treatment requirements: Participants entering Parts 2 and 3 must have at least 1 measurable lesion.

Part 1 and Part 2:

Eligible advanced/metastatic tumor types include NSCLC, urothelial carcinoma (UC), renal cell carcinoma (RCC), melanoma, head and neck squamous cell carcinoma (HNSCC), and microsatellite stable colorectal cancer (MSS-CRC). Participants must have demonstrated radiographic progression on standard treatment(s) for their cancer

Part 3:
* Cohort 1: Participants with metastatic melanoma with resistance to checkpoint inhibitor therapy and BRAF/MEKi.
* Cohort 2: Participants with metastatic MSS-CRC.
* Cohort 3: Participants with previously untreated metastatic NSCLC.
3. ECOG PS 0 or 1.

Exclusion Criteria

1. Participants with any other active malignancy within 3 years prior to enrollment.
2. Known or suspected hypersensitivity to, or severe allergic history of, human albumin or anti-PD-(L)1 therapy.
3. History of Grade ≥3 immune-related AE (irAE) or unresolved irAEs prior to first dose of study intervention. Exception: vitiligo and endocrinopathy that is controlled with hormonal therapy.
4. History of venous thromboembolic event \<12 weeks prior to starting study treatment.
5. Active or history of clinically significant gastrointestinal (GI) disease.
6. Active or history of interstitial lung disease or Grade ≥2 pneumonitis.
7. Active or history of clinically significant autoimmune disease.
8. Active bleeding disorder.
9. Participants who have undergone treatment with any investigational IL-12 agent.
10. Active, uncontrolled infections

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No